Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Rosuvastatin; Heart Failure; Positron Emission Tomography (PET)
Intervention: Rosuvastatin (Drug); Positron emission tomography (Procedure)
Phase: Phase 3
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
AstraZeneca CV Medical Department, Study Director, Affiliation: AstraZeneca BV
Summary
At one site, patients participating in the Corona main study are asked to participate in the
PET-substudy. Before and 6 months after study medication is started a Positron Emmission
Tomography (PET-scan) is performed to study the effect of rosuvastatin in Chronic Heart
Failure on myocardial perfusion (reserve)
Clinical Details
Official title: Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) PET Sub Study
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: To study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve). Before and 6 months after study medication is started a Positron Emmission Tomography (PET-scan) is performed.
Secondary outcome: To study the effect of rosuvastatin in Chronic Heart Failure on mismatch. Before and 6 months after study medication is started a Positron Emmission Tomography (PET-scan) is performed.
Eligibility
Minimum age: 60 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients fulfilling the in and exclusion criteria of the CORONA study and separate
informed consent for participation in the sub study.
Exclusion Criteria:
- See above
Locations and Contacts
Research Site, Groningen, Netherlands
Additional Information
Starting date: February 2004
Ending date: September 2007
Last updated: November 2, 2007
|
